Levi & Korsinsky, LLP announces that a ADMS class action lawsuit has been commenced on behalf of investors who purchased Adamas Pharmaceuticals, Inc. (ADMS) securities between August 8, 2017 and September 30, 2019. For more on the Adamas Pharmaceuticals Class Action please contact us today.

According to the Adamas Pharmaceuticals lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas’s primary product, GOCOVRI, from their prescription formularies or requiring patients to use “step therapy” – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company’s financial statements about Adamas’s business, operations, and prospects were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE ADMS CLASS ACTION, VISIT: https://www.zlk.com/pslra-1/adamas-pharmaceuticals-inc-loss-form?wire=9&prid=4837

If you suffered a loss in Adamas Pharmaceuticals you have until February 10, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com